|
Abstract:
|
With the advent of high-throughput proteomics, technologies for the measurement of large numbers of proteins or peptides have become available to biologists to study biological functions in cells directly. Identification of unique protein signatures would enable the development of new tools for proteomics-based, noninvasive screening of cancers. We will focus on the following issues related to the technology: quality control, normalization, methods of putative marker selection, and evaluation of those markers. As some of these issues are common to mass spectrometry data, our approach is generalizable to other MS platforms. We will illustrate our approach with an example from endometrial cancer, which uses cervical liquid PAP smear samples from women with and without endometrial cancer to identify unique changes in proteins/peptides.
|
